How Pharma CEOs Delegate Medical Affairs Operations

Medical affairs sits at one of the most structurally complex intersections in the pharmaceutical organization. It is simultaneously a scientific function (responsible for clinical evidence generation and dissemination), a regulatory function (operating under FDA promotional guidelines), and a commercial function (supporting product launches and lifecycle management). For a pharma or biotech CEO, delegating medical affairs means navigating all three dimensions while maintaining the scientific credibility that boards, investors, and KOLs expect from organizational leadership.

Most pharma CEOs who have a background in science or medicine are particularly prone to over-involvement in medical affairs. The work feels familiar. The KOL relationships often predate the CEO’s current role. The instinct to review every publication or weigh in on every advisory board agenda is understandable. But a medical affairs function that operates under CEO micromanagement cannot build the scientific independence that gives it credibility with the medical community.

This guide covers how to build a delegation structure that gives your Chief Medical Officer genuine authority, defines the boundaries of the medical-commercial divide, and preserves CEO involvement in the strategic KOL relationships that genuinely require executive presence.

Defining the CMO’s Authority Scope

Before effective delegation is possible, the CEO and CMO need explicit agreement on the scope of CMO authority. This is not a one-time conversation; it is a documented framework that gets revisited when organizational roles shift or new programs launch.

Full CMO Authority

Medical content and publications strategy. The decision to publish, what data to publish, and in which journals belongs entirely to the CMO and the medical team. CEO involvement in publication strategy decisions is appropriate only if a publication would have material board-reportable implications (e.g., safety data that affects product risk profile at a company-defining level).

MSL team strategy and deployment. The Medical Science Liaison team is a field medical function, not a commercial function. The CMO owns MSL deployment strategy, territory design, and the scientific exchange framework within which MSLs operate.

Advisory board scientific content. The scientific agenda for medical advisory boards (as distinct from commercial speaker programs) is CMO-owned. Which physicians are engaged as advisors, on what scientific questions, and with what deliverables is a medical affairs decision.

Medical information function. Responses to unsolicited medical information requests, including off-label inquiries, are medical affairs responsibilities managed under the CMO.

HEOR and real-world evidence strategy. Health economics and outcomes research, real-world evidence generation, and their integration into medical communications are CMO-led activities.

CEO Touchpoints in Medical Affairs

The CEO should be involved in medical affairs at four specific points:

Annual medical affairs strategy review. The CMO presents the annual medical plan to the CEO, covering publication goals, KOL engagement priorities, scientific congress strategy, and HEOR objectives. The CEO aligns this plan with commercial and pipeline strategy.
KOL relationship stewardship for tier-one KOLs. The CEO maintains personal relationships with a defined list of top scientific thought leaders, supported by CMO-managed engagement infrastructure. More on this below.
Medical-commercial boundary disputes. When the commercial team pushes for scientific activities that cross into promotional territory, the CEO arbitrates with strong deference to the CMO.
External scientific credibility moments. Advisory committee meetings, major congress presentations of pivotal data, and high-visibility peer-reviewed publications in top journals warrant CEO awareness and often CEO attendance.

The Medical-Commercial Boundary in Practice

No delegation question in pharmaceutical medical affairs is more fraught than the medical-commercial boundary. FDA regulations prohibit using medical affairs resources for promotional purposes. Internal policy should reinforce that boundary. But commercial teams are under revenue pressure and will test the boundary repeatedly if it is not maintained with CEO backing.

The CEO’s role in maintaining this boundary is structural, not supervisory. The structure includes:

Separate reporting lines. Medical affairs should report to the CMO, not to the Chief Commercial Officer. If your medical affairs function reports into commercial, the boundary is already compromised structurally. This is a CEO-level organizational design decision.

A cross-functional medical-commercial interface process. A defined process for commercial teams to request medical affairs support (for activities that are clearly within bounds, like formulary support with published data) prevents ad hoc requests that blur the boundary. The CMO owns this process.

CEO backing when the CMO enforces the boundary. If the CMO declines a commercial request on boundary grounds and the commercial team escalates to the CEO, the CEO’s default should be to support the CMO’s position. CEOs who routinely override CMO boundary calls signal to the organization that the boundary is negotiable.

Legal and compliance oversight. The General Counsel or Chief Compliance Officer should have standing visibility into medical-commercial boundary compliance. The CEO should receive an annual report from compliance on medical affairs promotional activity oversight.

KOL Engagement: Defining the CEO’s Tier

Key Opinion Leader engagement is one of the most high-value medical affairs activities and one of the most prone to delegation confusion. Every pharma CEO has a mental list of scientific leaders they know personally. The question is how to integrate those relationships into the medical affairs structure without creating a parallel CEO-run KOL program that undermines the CMO’s work.

The answer is a tiered KOL framework with explicit CEO and CMO ownership at each tier.

Tier One: CEO Relationship (Scientific Advisory Board Chairs, Top 5-10 Global KOLs)

These are the scientists whose endorsement of the company’s science creates real organizational value: advisory board chairs, potential principal investigators for pivotal studies, and the two or three international KOLs whose opinion shapes clinical practice in your therapeutic area.

The CEO maintains personal relationships with this tier: annual dinners, handwritten notes after major publications, personal calls when pivotal data is disclosed. The CMO and medical affairs team provide all logistical and scientific support for these interactions, including relationship timelines, briefing materials, and follow-up coordination.

Tier Two: CMO Relationship (National KOLs, Advisory Board Members)

The CMO personally engages this tier, attending advisory boards, participating in medical education events, and maintaining direct scientific dialogue. The CEO may interact with these KOLs at company events but does not manage these relationships.

Tier Three: MSL Relationships (Regional KOLs, Emerging Thought Leaders)

The MSL team owns these relationships entirely. The CMO reviews MSL territory plans and KOL mapping; the CEO does not.

This framework lets the CEO engage scientific leaders strategically without crowding the medical affairs function.

Publication Strategy: CEO Governance, CMO Execution

Publication strategy is where scientific credibility and commercial interests collide most visibly. A pharma company’s publication record is scrutinized by physicians, payers, regulators, and increasingly by the media. CEOs should understand publication strategy at a governance level without directing individual publication decisions.

The CEO governance role in publications includes:

Setting the expectation for publication integrity. The CEO should explicitly communicate to the CMO, commercial leadership, and the board that publication decisions are scientific decisions, not marketing decisions. This statement needs to be made regularly and backed up behaviorally.

Approving the annual publication plan at a strategic level. How many publications are planned, in which journals, on which data sets, is a strategic question that affects investor expectations and competitive positioning. The CEO should understand this plan.

Being informed of any publication that contains material safety or efficacy data. Before a high-impact publication goes out, the CEO should have read the abstract and key findings. Not to approve the science, but to be prepared for investor and media questions.

Being informed of any publication dispute. If a clinical investigator disputes authorship, if there is a disagreement with a journal about data presentation, or if a publication raises questions the commercial team believes are harmful, the CEO needs to know. These situations carry reputational risk.

The CMO owns everything below this governance level, including author selection, statistical analysis decisions, journal targeting, response to peer review, and timing of publication release.

Medical Affairs Metrics: What the CEO Should Track

Pharma CEOs who receive medical affairs updates often get activity reports (MSL calls completed, advisory boards convened, publications submitted) that tell them very little about whether the function is performing. The metrics that matter for CEO-level oversight are different.

Scientific exchange quality. Are KOLs engaged with the company’s science at a meaningful level? Are MSLs receiving invitations to present at academic institutions? Are scientific advisory board recommendations being incorporated into clinical and regulatory strategy?

Publication impact. What is the citation rate for company-sponsored publications? Are key publications in tier-one journals? Is the publication record advancing the scientific narrative that supports the asset’s commercial success?

Medical-commercial boundary integrity. Is the compliance function recording any promotional activity findings related to medical affairs? Are commercial teams routing requests through the appropriate channels?

Payer and formulary support. Is medical affairs providing the HEOR and real-world evidence data that payer and access teams need? Are formulary decisions reflecting the strength of the clinical evidence?

These metrics give the CEO genuine visibility into medical affairs performance without requiring the CEO to review MSL call logs or advisory board minutes.

Delegating Medical Affairs Across Multiple Assets

Biotech and specialty pharma companies often have multiple clinical-stage assets that each require medical affairs support. As the pipeline grows, the CMO faces resource allocation decisions that require CEO alignment.

The CEO and CMO should reach explicit agreement on:

Medical affairs investment by asset. Which programs receive proactive KOL development and publication support, and which receive reactive medical information support only, is a resource allocation decision with commercial implications. The CEO should weigh in at the annual strategy review.

Priority when medical affairs resources conflict. If the MSL team is asked to support both a pre-launch and a post-launch asset in the same therapeutic area, priority should be explicitly set, not resolved informally by the medical affairs director in the field.

External medical affairs partnerships. Contract medical affairs organizations are increasingly used to support specific programs. Decisions to use external partners for medical affairs, and at what scale, should be CEO-approved given the compliance implications.

According to Forbes research on pharmaceutical leadership, companies that maintain clear separation between medical and commercial functions while empowering CMOs with genuine strategic authority show stronger long-term scientific credibility and better payer relationships. For further reading, see Forbes Insights on pharma leadership and organizational design.

For pharma and biotech CEOs building broader delegation structures across the C-suite, the guide to CEO delegation in pharmaceutical and biotech organizations addresses how medical affairs authority intersects with clinical development and commercial leadership.

Common Delegation Failures in Medical Affairs

CEOs who attend advisory boards as content participants. If the CEO is at the table presenting scientific data at a medical advisory board, the CMO’s authority is implicitly diminished. CEO presence at advisory boards should be for opening remarks and strategic context, then exit.

CEOs who have direct MSL reporting relationships. Some CEOs form informal relationships with individual MSLs who provide real-time field intelligence. This creates an information channel that bypasses the CMO and can lead to distorted resource deployment.

CEOs who review publication drafts. Scientific publication review belongs to the CMO and the publication committee. CEO review of publication drafts is a signal that the CEO does not trust the CMO’s scientific judgment, which undermines the CMO’s authority with internal and external scientists.

CEOs who negotiate directly with KOLs about advisory board compensation. KOL financial arrangements are governed by fair market value requirements and anti-kickback considerations. Any CEO involvement in negotiating KOL compensation, even informally, creates compliance exposure.

The pharma CEO delegation framework for clinical development teams addresses parallel delegation questions for clinical operations, where the same medical-commercial boundary issues arise in a different operational context.

Building the CMO-CEO Partnership

Effective medical affairs delegation ultimately depends on the quality of the CEO-CMO relationship. A CMO who is uncertain about her authority will under-exercise it, creating the bottleneck the CEO was trying to avoid. A CMO who is over-confident about her independence will make strategic decisions without CEO alignment, creating board-level surprises.

The CEO-CMO relationship works well when:

The CMO has a standing weekly or biweekly one-on-one with the CEO
The CEO consistently backs the CMO’s decisions in cross-functional settings
The CMO proactively informs the CEO of anything with board or investor implications before it becomes public
The CEO raises concerns about medical affairs performance directly with the CMO, not through commercial or finance channels

This relationship is the backbone of effective medical affairs delegation. The structure and authority frameworks described throughout this article depend on it being strong.

Conclusion

Pharmaceutical and biotech CEOs who delegate medical affairs well are those who understand the distinction between scientific governance and scientific management. Governance belongs at CEO level: setting the expectation for integrity, establishing the medical-commercial boundary, and maintaining relationships with the scientific leaders whose endorsement shapes the field.

Management belongs with the CMO: building the MSL team, directing the publication strategy, leading advisory board science, and maintaining the day-to-day scientific relationships that give the organization credibility with prescribers and payers.

The CEO who holds the governance role while genuinely ceding the management role gives the CMO what she needs to build a medical affairs function that creates real organizational value.

For further context, explore How Pharma CEOs Delegate Business Development and Licensing and How Pharma CEOs Delegate Clinical Trial Operations.